

(flunixin meglumine) For the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.

ITEM#	DESCRIPTION	SIZE
503018	Prevail Equine Paste	30 g

FEATURES AND BENEFITS

- **Apple-flavored**
- Controls inflammatory response
- NSAID approved for oral administration
- Non-narcotic
- Non-steroidal; no steroidal side effects
- Active up to 36 hours
- Safe: Approved by FDA



Prevail™ Equine Paste



VET one® (flunixin meglumine)

Equine Paste

**For Oral Use in Horses Only.
NOT FOR HUMAN USE.**

**KEEP THIS AND ALL DRUGS OUT
OF REACH OF CHILDREN.**

**Caution: Federal law restricts this
drug to use by or on the order of
a licensed veterinarian.**

Activity: Flunixin meglumine is a potent, nonnarcotic, nonsteroidal, analgesic agent with anti-inflammatory and antipyretic activity. It is significantly more potent than pentazocine, meperidine, and codeine as an analgesic in the rat yeast paw test. Oral studies in the horse show onset of flunixin activity occurs within 2 hours of administration. Peak response occurs between 12 and 16 hours and duration of activity is 24 to 36 hours.

Contraindications: There are no known contraindications to this drug when used as directed.

Precautions: The effect of flunixin meglumine on pregnancy has not been determined. Studies to date show there is no detrimental effect on stallion spermatogenesis with or following the recommended dose of flunixin meglumine.

Side Effects: During field studies with flunixin meglumine, no significant side effects were reported.

Dosage and Administration: The recommended dose of flunixin meglumine is 0.5 mg per lb of body weight once daily. The Prevail Equine Paste syringe, calibrated in twelve 250-lb weight increments, delivers 125 mg of flunixin for each 250 lbs. One syringe will treat a 1000-lb horse once daily for 3 days, or three 1000-lb horses one time.

Dosage: The paste is orally administered by inserting the nozzle of the syringe through the interdental space, and depositing the required amount of paste on the back of the tongue by depressing the plunger.

Treatment may be given initially by intravenous or intramuscular injection of Prevail Injectable Solution, followed by Prevail Equine Paste on Days 2 to 5. Flunixin meglumine treatment should not exceed 5 consecutive days.

Toxicity: No toxic effects were observed in rats given oral flunixin meglumine 2 mg/kg per day for 42 days. Higher doses produced ulceration of the gastrointestinal tract. The emetic dose in dogs is between 150 and 250 mg/kg. Flunixin was well tolerated in monkeys dosed daily with 4 mg/kg for 56 days. No adverse effects occurred in horses dosed orally with 1.0 or 1.5 mg/lb for 5 consecutive days.

Storage Information: Store at 20°C - 25°C (68°F - 77°F); excursions permitted between 15°C - 30°C (between 59°F - 86°F).

How Supplied: Contains: 12 - Prevail (flunixin meglumine) Equine Paste Syringes 30 g each (syringe contains flunixin meglumine equivalent to 1500 mg flunixin).



Rev. 01/18



VetOne products are sold exclusively through MWI Animal Health ☎ 800.824.3703 🌐 mwiah.com
For product information, log on to your MWI website account or visit 🌐 vetone.net

